Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ashley Gordon

Plastic Surgery Austin, TX Medical Doctor

NPI 1124048343 CMS profile 50151

901 W 38Th St, Suite 401, Austin, TX 78705

Open in the dashboard

General payments

$18,013

108 records reported · program years 2019–2025

Research payments

$16,000

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ashley Gordon of Austin, TX is reported in the CMS Open Payments database as having received $18,013 across 108 general payments and $16,000 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,038 17
2024 General $3,173 14
2023 General $5,918 35
2022 General $1,673 15
2022 Research $8,250 1
2021 General $629 9
2021 Research $7,750 1
2020 General $51 3
2019 General $1,531 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ashley Gordon
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Ashley Gordon were reported at $5,038. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Ashley Gordon Plastic Surgery median Middle half National median
2019 $1,531 $371 $122–$1,483 $163
2020 $51 $158 $52–$438 $114
2021 $629 $249 $87–$752 $132
2022 $1,673 $274 $102–$793 $149
2023 $5,918 $299 $113–$891 $160
2024 $3,173 $361 $124–$1,062 $164
2025 $5,038 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Motiva USA, LLC $7,513 21 payments
  2. Sientra, Inc. $4,598 23 payments
  3. Merz North America, Inc. $2,546 16 payments
  4. Davol Inc. $1,731 14 payments
  5. Tepha Inc $471 5 payments
  6. AbbVie, Inc. $345 7 payments
  7. Mentor Worldwide LLC $173 3 payments
  8. Becton, Dickinson and Company $142 1 payment
  9. Allergan Inc. $134 3 payments
  10. Galderma Laboratories, L.P. $118 6 payments
  11. Other $243 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,901 90 payments
  2. Consulting Fee $4,500 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,000 12 payments
  4. Travel and Lodging $1,525 2 payments
  5. Gift $87 1 payment
Products named General payments · program years 2019–2025
  1. Motiva Implant Matrix Devices $4,865 15 payments
  2. SIENTRA HIGH STRENGTH COHESIVE SILICONE GEL BREAST IMPLANT $4,598 23 payments
  3. Motiva Implant Matrix Plastic Surgery $2,601 5 payments
  4. Xeomin musculoskeletal $1,779 8 payments
  5. Phasix Mesh BD Interventional Surgery $761 6 payments
  6. Phasix Mesh Surgery $685 5 payments
  7. GalaFLEX $471 5 payments
  8. NATRELLE SALINE-FILLED BREAST IMPLANTS $290 4 payments
  9. Xeomin Dermatology $250 4 payments
  10. ARISTA AH FlexiTip $239 2 payments
  11. Other $680 12 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sientra, Inc. $16,000 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

126

Median for Plastic Surgery: 39

Drug cost

$837

Median for Plastic Surgery: $219

Branded share of claims

16.7%

Median for Plastic Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 11 $340
Valacyclovir Valacyclovir Hcl Brand 21 $217
Cephalexin Generic 13 $91
Gabapentin Generic 27 $61
Oxycodone Hcl Generic 14 $46
Promethazine Hcl Generic 13 $43
Diazepam Generic 11 $21
Montelukast Sodium Generic 16 $18

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 700 Part D prescribers listed as Plastic Surgery; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Xeomin
  • MERZ NORTH AMERICA, INC. $117
$117 — —
DAXXIFY
  • REVANCE THERAPEUTICS, INC. $42
$42 — —
BOTOX
  • AbbVie, Inc. $21
$21 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

110 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record